yh35324
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 26, 2021 (NCT05061524)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Immunoglobulin epsilon Fc receptorINHIBITOR
FCER2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05960708 | Phase 1 | Aug 23, 2023 | Ajou University, Yuhan Pharmaceutical Company |
| NCT05564221 | Phase 1 | Nov 1, 2022 | Ajou University, Yuhan Pharmaceutical Company |
| NCT05061524 | Phase 1 | Sep 26, 2021 | Yuhan Pharmaceutical Company |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Yuhan Pharmaceutical Company | For profit | 3 | 3 | 1 | 2021 |
| Ajou University | Academic/Hospital | 2 | 0 | 1 | 2022 |
2 organizations
Page 1 / 1